Overview

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Status:
Unknown status

Trial end date:
2020-09-30

Target enrollment:

Participant gender:

Summary

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University